thrombolytic-plus-anticoagulant therapy versus anticoagulant-alone therapy in submassive pulmonary thromboembolism (tvaspe study): a randomized clinical trial
نویسندگان
چکیده
background: the use of thrombolytic agents in the treatment of hemodynamically stable patients with acute submassive pulmonary embolism (pte) remains controversial. we, therefore, conducted this study to compare the effect of thrombolytic plus anticoagulation versus anticoagulation alone on early death and adverse outcome following submassive pte. methods: w e conducted a study of patients with acute pulmonary embolism and pulmonary hypertension or right ventricular dilatation/dysfunction but without arterial hypotension or shock. the patients were randomly assigned in a single-blind fashion to receive an anticoagulant [enoxaparin (1 mg/kg twice a day)] plus a thrombolytic [alteplase (100 mg) or streptokinase (1500000 u/2 hours)] or an anticoagulant [enoxaparin (1 mg/kg twice a day)] alone. the primary endpoint was in-hospital death or clinical deterioration requiring an escalation of treatment. the secondary endpoints of the study were major bleeding, pulmonary hypertension, right ventricular dilatation at the end of the first week, and exertional dyspnea at the end of the first month. results: of 50 patients enrolled, 25 patients were randomly assigned to receive an anticoagulant plus a thrombolytic and the other 25 patients were given an anticoagulant alone. the incidence of the primary endpoints was significantly higher in the anticoagulant-alone group than in the thrombolytic-plus-anticoagulant group (p value = 0.022). at the time of discharge, pulmonary artery pressure was significantly higher in the anticoagulant-alone group than in the thrombolytic- plus-anticoagulant group (p value = 0.018); however, reduction in the right ventricular size or normalization of the right ventricle showed non-significant differences between the two groups. there was no significant difference regarding the new york heat association (nyha) functional class between the two groups at the end of the first month (p value = 0.213). no fatal bleeding or cerebral bleeding occurred in the patients receiving an anticoagulant plus a thrombolytic. conclusion: when given in conjunction with anticoagulants, thrombolytics may improve the clinical course of stable patients who have acute submassive pulmonary embolism and prevent clinical deterioration.
منابع مشابه
Thrombolytic-plus-Anticoagulant Therapy versus Anticoagulant-Alone Therapy in Submassive Pulmonary Thromboembolism (TVASPE Study): A Randomized Clinical Trial
BACKGROUND The use of thrombolytic agents in the treatment of hemodynamically stable patients with acute submassive pulmonary embolism (PTE) remains controversial. We, therefore, conducted this study to compare the effect of thrombolytic plus anticoagulation versus anticoagulation alone on early death and adverse outcome following submassive PTE. METHODS We conducted a study of patients with ...
متن کاملThrombolytic and anticoagulant therapy for acute submassive pulmonary embolism
This study aimed to compare the efficacy and safety of thrombolytic and anticoagulant therapy for acute submassive pulmonary embolism (PE). A retrospective evaluation was performed on 25 consecutive inpatients with acute submassive PE treated by thrombolytic therapy and 25 earlier consecutive inpatients with acute submassive PE treated by anticoagulant therapy. No statistically significant diff...
متن کاملRecurrence of idiopathic thromboembolism during anticoagulant therapy.
Patients with acute pulmonary embolism and venous thromboembolism are usually treated with anticoagulant therapy for at least 3 months as the optimum duration. A patient with recurrent idiopathic venous thromboembolism at the eighth month during anticoagulation (warfarin to target international normalized ratio of 2.0-3.0) is described. The case suggests that patients with idiopathic venous thr...
متن کاملThe Belgian Improvement Study in Oral Anticoagulant Therapy: a randomized clinical trial
We read with great interest the article by Claes et al. about The Belgian Improvement Study on Oral Anticoagulant Therapy. The randomized clinical trial compares different interventional models to improve the quality of oral anticoagulant therapy in general practitioners’ (GP’s) practice who mainly manage the control of anticoagulation. In Hungary, arterial and venous vessel diseases have a gre...
متن کاملDuration of anticoagulant therapy for venous thromboembolism.
The Medical Journal of Australia ISSN: 0025729X 15 June 2009 190 12 659-660 ©The Medical Journal of Australia 2009 www.mja.com.au Editorials days with unfractionated heparin, low-molecular-wei fondaparinux, prevents thrombus progression and re of recurrent VTE and death during the acute ph treatment is continued beyond the acute phase, wa the risk of recurrent VTE but increases the risk of requ...
متن کاملThe Belgian Improvement Study in Oral Anticoagulant Therapy: a randomized clinical trial.
We read with great interest the article by Claes et al. about The Belgian Improvement Study on Oral Anticoagulant Therapy. The randomized clinical trial compares different interventional models to improve the quality of oral anticoagulant therapy in general practitioners’ (GP’s) practice who mainly manage the control of anticoagulation. In Hungary, arterial and venous vessel diseases have a gre...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
the journal of tehran university heart centerجلد ۹، شماره ۳، صفحات ۱۰۴-۱۰۸
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023